Subject(s)
Food Deprivation/physiology , Meat/analysis , Muscle Proteins/analysis , Muscle, Skeletal/physiology , Animals , Enzyme-Linked Immunosorbent Assay , Female , Hindlimb , Immunoblotting , Immunoglobulins/analysis , Muscle Proteins/immunology , Muscle, Skeletal/immunology , Poultry , TurkeysABSTRACT
Recombinant bovine somatotropin (rBST) treatment is adopted in dairy cows to augment milk yield. Previous studies showed that insulin-like growth factor-1 (IGF-1) is present in milk from cows treated with rBST. Since IGF-1 is a suspected carcinogen, its presence in milk for human consumption is potentially a health hazard. Therefore rBST use, still authorized in the United States, has been revoked in Canada and is under evaluation in the EU. The rising attention on IGF-1 presence in alimentary milk focused the necessity to develop specific, sensitive and rapid IGF-1 detection systems. We have developed a solid phase enzyme-linked immunoassay (ELISA) and also an automated surface plasmon resonance-based biosensor system (BIA-technology) for evaluating IGF-1 in fresh cow's milk. Hyperimmune polyclonal anti-IGF-1 antibodies were characterized with respect to their specific binding capacity to IGF-1. The results obtained with these two methods have been compared. This study shows the potential usefulness of the biosensor technology for biomolecular interaction analysis. The features of this technology (fully automated, measures in real time, sharpened yes/no response) offer several advantages compared to ELISA in the detection of compounds in fresh cows' milk (MURST 40%; CNR P.F. MADESS 2).
Subject(s)
Enzyme-Linked Immunosorbent Assay/methods , Insulin-Like Growth Factor I/analysis , Milk/chemistry , Surface Plasmon Resonance/methods , Animals , Cattle , Food Contamination/analysis , Growth Hormone/pharmacology , Humans , Insulin-Like Growth Factor I/adverse effects , Recombinant Proteins/pharmacologyABSTRACT
This study analyzed the cost-effectiveness of antibiotic treatments of different durations for acute cystitis in non-pregnant females. Questionnaires were sent to 400 practitioners evenly distributed throughout Italy. Data are reported from 2,069 patients. The clinical bacteriological efficacy at 10-15 days was 86.4% for single-dose treatment with fosfomycin-trometamol (FT), and 81.8% for the multiple-dose antibiotics group (MDAG). Disappearance of symptoms occurred in 2.1 days with FT and 3.4 days with MDAG. With FT 93.8% of patients were free of adverse events and 86.9% with MDAG. Analysis of the cost-effectiveness indicators for cure rate and absence of adverse events showed that treatment costs were similar for all antibiotics. FT needed less time interval for symptoms to disappear with a slightly higher cost than for MDAG, which had a better cost/effectiveness ratio.
Subject(s)
Anti-Bacterial Agents/economics , Drug Therapy, Combination/economics , Urinary Tract Infections/drug therapy , Adult , Anti-Bacterial Agents/administration & dosage , Cephalosporins/administration & dosage , Cephalosporins/economics , Cost-Benefit Analysis , Drug Administration Schedule , Drug Therapy, Combination/administration & dosage , Female , Fosfomycin/administration & dosage , Fosfomycin/economics , Humans , Piperacillin/administration & dosage , Piperacillin/economics , Time Factors , Tromethamine/administration & dosage , Tromethamine/economicsABSTRACT
In order to assess the resistance profile for fosfomycin trometamol after several years of clinical use in Italy, this study has explored the susceptibility to fosfomycin and eight other antibacterial drugs of 6,021 strains isolated from 23,816 urines during 1990 in three teaching hospitals located in Genoa, Parma and Catania. Gram-negative strains, notably Escherichia coli (41.6%), were primarily involved. Amoxicillin was the least active compound with resistance in 41.4% of the isolates. Fosfomycin showed the lowest rate of resistance in both gram-negative (2.8%) and gram-positive (2.1%) pathogens. This was followed by norfloxacin with a resistance rate of 11.8% and netilmicin with 12.2%. These results indicate that fosfomycin-trometamol may continue to be used in single-dose treatment of urinary tract infections even in the absence of microbiological data since the prevalence of resistance to the drug is, at present, so low that therapeutic failure is highly improbable.
Subject(s)
Anti-Bacterial Agents/pharmacology , Enterobacteriaceae/drug effects , Fosfomycin/pharmacology , Gram-Positive Cocci/drug effects , Urinary Tract Infections/microbiology , Anti-Infective Agents, Urinary/pharmacology , Drug Resistance, Microbial , Humans , Italy , Microbial Sensitivity TestsSubject(s)
Cystitis/drug therapy , Cystitis/economics , Fosfomycin/analogs & derivatives , Tromethamine/analogs & derivatives , Acute Disease , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Cost-Benefit Analysis , Fosfomycin/administration & dosage , Fosfomycin/economics , Humans , Tromethamine/administration & dosage , Tromethamine/economicsABSTRACT
Two families are described with members affected by Brown's syndrome. Another case of Brown's syndrome is described in a dizygotic twin. The authors suggest a hypothesis for the influence of heredity in Brown's syndrome.
Subject(s)
Movement Disorders/genetics , Oculomotor Muscles , Child , Child, Preschool , Eye Movements , Female , Humans , Male , Movement Disorders/physiopathology , Pedigree , SyndromeABSTRACT
The case of a 2 year old girl with myasthenia gravis is reported. Immunological investigations did not show any major abnormalities of the thymocytes. High levels of acetylcholine receptor antibodies were present before thymectomy. After surgery they decreased significantly and there was a clear clinical improvement.
